MAGED4 and central nervous system cancer: Since the demethylation of the MAGE-D4 promoter enhances promoter activity (8), pyrosequencing was used to analyze the methylation status of 18 CpG sites in two regions of the MAGE-D4 core promoter region in glioma cells treated with epigenetic drugs.